All News

This is based on results of a new study reported in Mayo Clinic Proceedings.

A new report from Decision Resources found that Florida leads the pack with most untreated Type 2 diabetics who also have drug coverage.

Physicians' negative experience with Exubera, Pfizer/Nektar's inhaled insulin, may slow adoption of new therapies.

CVS is already the largest drug chain in the country.

The purchase is expected to expand the enrollment of the campus by up to 400 students.

That's one of the conclusions of a new survey report by Decision Resources.

The FDA said patients should monitor the injection site.

The drug is administered as a once-daily tablet.

The school and sports physicals cost $25.

FDA still receiving many adverse incidents about the concurrent administration of the two products.

Recall happened because patches leaking fentanyl gel have been detected.

More than 600 bouquets were sent to the site.

A new machine allows pharmacists to accept disposable sharps from consumers and convert them into compact waste that can be thrown in the trash bin.

A group called the Cancer Prevention Coalition is charging that the Food and Drug Administration is asleep at the wheel regarding sunscreens.

Publications are designed to improve management skills, enhance pharmacists' image, and help reduce stress.

Some confusion exists among the medical community and the general public about the toxicity and resistance among prescription lice treatments.

A pending Federal Trade Commission (FTC) report, expected later this year, may settle the decade-old dispute as to whether authorized generics are legal. With billions of dollars at stake, the loser will undoubtedly challenge the government's decision.

Traditionally, generics industry executives are tight-lipped about their business plans. But Drug Topics managed to corral five industry leaders who opened up about their hopes, fears, and challenges:

Are $4 generics the future of pharmacy? Perhaps so, as the consumption of generic drugs soars and their costs drop. Wal-Mart, which beat a thorny path to what many pharmacists believe is loss-leader pricing, says $4 was a great move. It is very popular-and good for business.

Consumers have never had more choices when it comes to treating their tootsies. Today's foot-care category boasts a solid mix of products designed to treat corns, calluses, bunions, warts, odor, wetness, and fungus. Also lining the foot-care shelves are orthotics, insoles, and inserts, along with popular foot grooming items.

MIPPA law delays implementation of Medicaid's average manufacturers price for generic drugs until Oct. 1, 2009.

The evolution of MRSA has led to reduced efficacy of vancomycin therapy.

Reimbursement for radiopharmaceuticals will be maintained at the 2007 rate through Jan. 1, 2010, thanks to the Medicare Improvements for Patients and Providers Act of 2008.

Medication errors continue to occur between the established name prophylthiouracil, often abbreviated as PTU.

The battle by pharmacy benefit management companies to limit fiduciary disclosure laws continues, with its trade group, the Pharmaceutical Care Management Association, scoring a victory in the District of Columbia.

NACDS backs legislation to adopt health information technology.

Medication management and safety errors were prominent topics at the American Society of Health-System Pharmacists summer meeting in June.

Of more than 4,000 cancer studies presented at the recent annual meeting of the American Society of Clinical Oncology, those exploring effects of targeted therapy cetuximab combined with platinum-based chemotherapy generated the most buzz.